PL426332A1 - Chemical compounds used as diagnostic markers of inflammation and cancer, method of their preparation, diagnostic kit and method of diagnosing inflammatory processes and epithelial cancers - Google Patents

Chemical compounds used as diagnostic markers of inflammation and cancer, method of their preparation, diagnostic kit and method of diagnosing inflammatory processes and epithelial cancers

Info

Publication number
PL426332A1
PL426332A1 PL426332A PL42633218A PL426332A1 PL 426332 A1 PL426332 A1 PL 426332A1 PL 426332 A PL426332 A PL 426332A PL 42633218 A PL42633218 A PL 42633218A PL 426332 A1 PL426332 A1 PL 426332A1
Authority
PL
Poland
Prior art keywords
inflammation
cancer
diagnostic
preparation
compounds used
Prior art date
Application number
PL426332A
Other languages
Polish (pl)
Other versions
PL236125B1 (en
Inventor
Adam LESNER
Natalia Gruba
Original Assignee
Uniwersytet Gdański
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Gdański filed Critical Uniwersytet Gdański
Priority to PL426332A priority Critical patent/PL236125B1/en
Priority to EP18183815.2A priority patent/EP3431490B1/en
Priority to PL18183815T priority patent/PL3431490T3/en
Priority to PCT/PL2019/050004 priority patent/WO2020017984A1/en
Publication of PL426332A1 publication Critical patent/PL426332A1/en
Publication of PL236125B1 publication Critical patent/PL236125B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Przedmiotem zgłoszenia są nowe związki mające zastosowanie w diagnostyce stanu zapalnego i nowotworów. Pierwsze dwa związki to związek o wzorze ogólnym: ABZ1-Leu2-Glu3-Pro4-Val5-X6, gdzie: ABZ oznacza kwas 2-aminobenzoesowy, X to oznacza ANB-NH2 lub pNA, przy czym ANB-NH2 oznacza amid kwasu 5-amino-2-benzoesowego, zaś pNA oznacza 4-nitroanilinę. Kolejny związek to: związek o wzorze ogólnym: ABZ1-Met2-Lys3-Val4-Trp5-pNA6 gdzie: ABZ oznacza kwas 2-aminobenzoesowy, pNA oznacza 4-nitroanilinę. Przedmiotem zgłoszenia jest również sposób otrzymywania nowych związków, marker diagnostyczny, zestaw diagnostyczny do zastosowania we wczesnej diagnostyki nowotworu nabłonkowego i/lub stanu zapalnego, sposób diagnozowania nowotworu nabłonkowego i/lub procesu zapalnego w materiale biologicznym ssaka.The subject of the application are new compounds used in the diagnosis of inflammation and cancer. The first two compounds are a compound of the general formula: ABZ1-Leu2-Glu3-Pro4-Val5-X6, where: ABZ is 2-aminobenzoic acid, X is ANB-NH2 or pNA, and ANB-NH2 is 5-amino acid amide -2-benzoic acid and pNA is 4-nitroaniline. Another compound is: a compound of the general formula: ABZ1-Met2-Lys3-Val4-Trp5-pNA6 where: ABZ is 2-aminobenzoic acid, pNA is 4-nitroaniline. The subject of the application is also a method for the preparation of new compounds, a diagnostic marker, a diagnostic kit for use in the early diagnosis of epithelial cancer and / or inflammation, a method for diagnosing epithelial cancer and / or an inflammatory process in biological material of a mammal.

PL426332A 2017-07-17 2018-07-14 Chemical compounds used as diagnostic markers of inflammation and cancer, method of their preparation, diagnostic kit and method of diagnosing inflammatory processes and epithelial cancers PL236125B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL426332A PL236125B1 (en) 2018-07-14 2018-07-14 Chemical compounds used as diagnostic markers of inflammation and cancer, method of their preparation, diagnostic kit and method of diagnosing inflammatory processes and epithelial cancers
EP18183815.2A EP3431490B1 (en) 2017-07-17 2018-07-16 Chemical compounds for use as diagnostic markers of inflammation and neoplams, the method for synthesis of the chemical compounds, diagnostic kit for use in diagnosis of inflammatory processes and epithelial neoplasms and in vitro diagnostic method of inflammatory processes and epithelial neoplasms
PL18183815T PL3431490T3 (en) 2017-07-17 2018-07-16 Chemical compounds for use as diagnostic markers of inflammation and neoplams, the method for synthesis of the chemical compounds, diagnostic kit for use in diagnosis of inflammatory processes and epithelial neoplasms and in vitro diagnostic method of inflammatory processes and epithelial neoplasms
PCT/PL2019/050004 WO2020017984A1 (en) 2018-07-14 2019-01-21 Chemical compounds for use as diagnostic markers of inflammation and neoplasms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL426332A PL236125B1 (en) 2018-07-14 2018-07-14 Chemical compounds used as diagnostic markers of inflammation and cancer, method of their preparation, diagnostic kit and method of diagnosing inflammatory processes and epithelial cancers

Publications (2)

Publication Number Publication Date
PL426332A1 true PL426332A1 (en) 2020-01-27
PL236125B1 PL236125B1 (en) 2020-12-14

Family

ID=65686914

Family Applications (1)

Application Number Title Priority Date Filing Date
PL426332A PL236125B1 (en) 2017-07-17 2018-07-14 Chemical compounds used as diagnostic markers of inflammation and cancer, method of their preparation, diagnostic kit and method of diagnosing inflammatory processes and epithelial cancers

Country Status (2)

Country Link
PL (1) PL236125B1 (en)
WO (1) WO2020017984A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009911A1 (en) * 2002-01-31 2004-01-15 Irm, Llc Hepsin substrates and prodrugs
EA200801822A1 (en) * 2008-06-19 2009-04-28 Ано "Институт Молекулярной Диагностики" TEST SYSTEM FOR DIAGNOSTIC PROSTATE CANCER AND METHOD OF DIAGNOSTIC PROSTATE CANCER
PL225341B1 (en) * 2014-07-17 2017-03-31 Univ Gdański New compound, method for obtaining it, pharmaceutical solution containing the new compound, method for determination of the presence of tumor disease, accessories for cancer detection and application of the hydrolysis of the new compound for cancer detection

Also Published As

Publication number Publication date
WO2020017984A1 (en) 2020-01-23
PL236125B1 (en) 2020-12-14

Similar Documents

Publication Publication Date Title
CY1124148T1 (en) THERAPEUTIC AGENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH UNDESIRABLE CELL PROLIFERATION
AR063493A1 (en) NEW ANTI NOTCH 3 ANTIBODIES AND THEIR USE FOR DETECTION AND DISEASE DIAGNOSIS
DOP2021000216A (en) 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS
BR112018010933A2 (en) multispecific antibodies
BR112016020752A2 (en) Isolated antibody or antigen-binding fragment thereof, pharmaceutical composition, and methods for treating a cancer or tumor expressing egfrviii and for treating a cancer, reducing tumor growth and / or causing tumor regression in a patient ?
BR112012033406A2 (en) antibody for cancer diagnosis and / or prognosis
MX2012011636A (en) Antibody recognizing human leukemia inhibitory factor (lif) and use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation.
EP3907509A3 (en) Diagnosis of early stage pancreatic cancer
CL2022002946A1 (en) Binding antibodies to acid ph sight (divisional application of 202100012)
BR112013021056A2 (en) monoclonal antibody, hybridoma cell line, diagnostic kit, methods for producing a monoclonal antibody and binding agent, purified amino acid sequence binding agent, method for obtaining a coding nucleic acid sequence, antibody molecule encoding isolated nucleic acid, vector, isolated host cell, fusion protein, screening method for the presence of a disease, a condition, methods of diagnosing an individual, prognosis for an individual, and monitoring an individual, and , method for detecting the presence or absence of cervical cancer
PE20180930A1 (en) COMPOSITIONS AND METHODS FOR ACTIVE SURVEILLANCE FOR PROSTATE CANCER
MX2024012382A (en) ANTI-TDP-43 BINDING MOLECULES
MX2024002720A (en) ANTI-4-1BB NANOBODIES.
DE60306517D1 (en) METHOD FOR DETECTING AND QUANTIFYING TUMOR CELLS DERIVED FROM TOMORROWING TUMOR CELLS
PL426332A1 (en) Chemical compounds used as diagnostic markers of inflammation and cancer, method of their preparation, diagnostic kit and method of diagnosing inflammatory processes and epithelial cancers
EP2029745A4 (en) DIAGNOSTIC METHODS AND MARKERS
ATE545867T1 (en) I-PLASTIN TEST METHOD FOR IN VITRO DIAGNOSIS OF COLORECTAL CARCINOMA
ES2570609T3 (en) Method for testing aminoacylase 1 for in vitro diagnosis of colorectal cancer
PL408905A1 (en) New compound, method for obtaining it, pharmaceutical solution containing the new compound, method for determination of the presence of tumor disease, accessories for cancer detection and application of the hydrolysis of the new compound for cancer detection
PL434554A1 (en) Chemical compounds used as diagnostic markers of inflammation and cancer to be used as a diagnostic kit, and method of diagnosing and differentiating inflammatory processes and epithelial cancers
RU2016109457A (en) DIAGNOSTIC DEVICE FOR DETERMINING TARGET STRUCTURES ASSOCIATED WITH THE DISEASE
PL434553A1 (en) Chemical compound used as a diagnostic marker of cancer, method of its preparation, method of diagnosing epithelial cancers
PL436999A1 (en) Serum copper concentration as a prognostic marker in patients with prostate cancer in Poland
PL426138A1 (en) Method of diagnosing Lyme disease, method of differential diagnosis of Lyme arthrisis, lysophosphatidylethanolamine to be used as a biomarker, set for diagnosing Lyme disease and set for differential diagnosis of Lyme arthrisis
EA200802356A1 (en) METHOD OF IDENTIFICATION AND DIAGNOSTICS OF MALIGNANT NORMALIZATION, INCLUDING PRIMERS AND PROBES FOR SPECIFIC MAG-A3 MARKER